



### UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT United States Patent and Tradenwirk Office Washington, D.C. 20231 www.usptb.gcv

 U.S. APPLICATION NUMBER NO.
 FIRST NAMED APPLICANT
 ATTY. DOCKET NO.

 09/720,045
 Jacques Bauer
 GEI-084

 20311
 PCT/IB99/01170

 MUSERLIAN AND LUCAS AND MERCANTI, LLP
 1.A. FILING DATE
 PRIORITY DATE

 06/23/1999
 06/30/1998

20311 MUSERLIAN AND LUCAS AND MERCANTI, LLP 600 THIRD AVENUE NEW YORK, NY 10016

CONFIRMATION NO. 6820
371 FORMALITIES LETTER
\*OC000000009556376\*

Date Mailed: 02/26/2003

## NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Listing
- Claims
- Drawings
- Initial Application Filing Fees
- Oath or Declaration
- Original Specification

Applicant's response filed 12/18/2000 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 06/12/2002 have not been completed.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - Paper 9 filed Sep 15, 2002 is noted as indicating no sequence listing and no CFR is needed, however, page 28, line 10 containes the tetrapeptide sequence "...Ile-Glu Ala-Arg-p-nitroanaline". This is a sequence of 4 amino acid residues. 37 C.F.R. 1.821 indicates that four (4) or more defined residues in a sequence require a sequence listing.

### ■ APPLICANT MUST PROVIDE:

- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

### ANITA D JOHNSON

Telephone: (703) 305-3661

# PART 2 - OFFICE COPY

	***************************************	
U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
09/720,045	PCT/IB99/01170	GEI-084

FORM PCT/DO/EO/916 (371 Formalities Notice)